Relationship of p53 Overexpression and Up-Regulation of Proliferating Cell Nuclear Antigen with the Clinical Course of Non-Small Cell Lung Cancer

Cancer Research

Volumn 54, Issue 9, 1994, Pages 2496-2503

  Steinberg, Seth M ^a   Mulshine, James L ^a   Linnoila, R Ilona ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SKIN METASTASIS; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0028224376     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Hollstein, M. Sidransky, D. Vogelstein, B. and Harris, C. p. 3 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
2. Takahashi, T. Nau, N.M. Chiba, I. Birrer, M.J. Rosenberg, R.K. Vinocour, M. Levitt, M. Pass, H. Gazdar, A.F. and Minna, J.D. p. 3: a frequent target for genetic abnormalities in lung cancer. Science (Washington DC), 246: 491-494, 1989.
3. Chiba, I. Takahashi, T. Nau, M.M. D'Amico, D. Curiel, D.T. Mitsudomi, T. Buchhagen, D.L. Carbone, D. Piantadosi, S. Koga, H. Reissmann, P. Slamon, D.J. Holmes, E.C. and Minna, J.D. Mutations in the p. 3 gene are frequent in primary, resected non-small cell lung cancer. Oncogene, 5: 1603-1610, 1990.
4. Ulrich, S.J. Anderson, C.W. Mercer, W.E. and Appella, E. The p. 3 tumor suppressor protein, a modulator of cell proliferation. J. Biol. Chem. 267: 1525915262, 1992.
5. Yin, Y. Tainsky, M.A. Bischoff, F.Z. Strong, L.C. and Wahl, G.W. Wild-type p. 3 restores cell cycle control and inhibits gene amplification in cells with mutant p. 3 alleles. Cell, 70: 937-948, 1992.
6. Hartwell, L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell, 71: 543-546, 1992.
7. Stenger, J.E. Mayr, G.A. Mann, K. and Tegtmeyer, P. Formation of stable p. 3 hemotetramers and multiple of tetramers. Mol. Carcinog. 5: 102-106, 1992.
8. Vogelstein, B. and Kinzler, K.W. p. 3 function and dysfunction. Cell, 70: 523-526, 1992.
9. Ginsberg, D. Mechta, F. Yaniv, M. and Oren, M. Wild-type p. 3 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA, 88: 9979-9983, 1991.
10. Taylor, W.R. Egan, S.E. Mowat, M. Greenberg, A.H. and Wright, J.A. Evidence for synergistic interactions between ras, myc and a mutant form of p. 3 in cellular transformation and tumor dissemination. Oncogene, 7: 1383-1390, 1992.
11. Lu, X. Park, S.H. Thompson, T.C. and Lane, D.P. ras-induced hyperplasia occurs with mutation of p. 3, but activated ras and myc together can induce carcinoma without p. 3 mutation. Cell, 70: 153-161, 1992.
12. Bodner, S.M. Minna, J.D. Jensen, S.M. D'Amico, D. Carbone, D. Mitsudomi, T. Fedorko, J. Buchhagen, D.L. Nau, M.M. Gazdar, A.F. and Linnoila, R.I. Expression of mutant p. 3 proteins in lung cancer correlates with the class ofp. 5 gene mutation. Oncogene, 7: 743-749, 1992.
13. Kupryjanczyk, J. Thor, A.D. Beauchamp, R. Merritt, V. Edgerton, S.M. Bell, D.A. and Yandell, D.W. p. 3 gene mutations and protein accumulation in human ovarian cancer. Proc. Natl. Acad. Sci. USA, 90: 4961-4965, 1993.
14. Teneriello, M.G. Ebina, M. Linnoila, R.I. Henry, M. Nash, J.D. Park, R.C. and Birrer, M.J. p. 3 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 53: 1-6, 1993.
15. Mitsudomi, T. Steinberg, S.M. Nau, M.M. Carbone, D. D'Amico, D. Bodner, S. Oie, H.K. Linnoila, R.I. Mulshine, J.L. Minna, J.D. and Gazdar, A.F. p. 3 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene, 7: 171-180, 1992.
16. Hinds, P.W. Finlay, C.A. Quartin, R.S. Baker, S.J. Fearon, E.R. Vogelstein, B. and Levine, A.J. Mutant p. 3 cDNA clones from human colon carcinomas can cooperate with ras in transforming primary rat cells: a comparison of the “Hot Spot” mutant phenotypes. Cell Growth & Differ. 1: 571-580, 1990.
17. Levine, A.J. Momand, J. and Finlay, C.A. The p. 3 tumor suppressor gene. Nature (Lond.), 351: 453-456, 1991.
18. McLaren, R. Kuzu, I. Dunnill, M. Harris, A. Lane, D. and Gatter, K.C. The relationship of p. 3 immunostaining to survival in carcinoma of the lung. Br. J. Cancer, 66: 735-738, 1992.
19. Horio, Y. Takahashi, T. Kuroishi, T. Hibi, K. Suyama, M. Niimi, T. Shimokata, K. Yamakawa, K. Nakamura, Y. Ueda, R. Takahashi, T. Prognostic significance of p. 3 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res, 53: 1-4, 1993.
20. Quinlan, D.C. Davidson, A.G. Summers, C.L. Warden, H.E. and Doshi, H.M. Accumulation of p. 3 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 52: 4828-4831, 1992.
21. Fontanini, G. MacChiarini, P. Pepe, S. Ruggiero, A. Hardin, M. Bigini, D. Vignati, S. Pingitore, R. and Angeletti, C.A. The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer. Cancer (Phila.), 70: 1520-1527, 1992.
22. Visakorpi, T. Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma. J. Pathol. 168: 7-13, 1992.
23. Shin, D.M. Voravud, N. Ro, J.Y. Lee, J.S. Hong, W.K. and Hittelman, W.N. Sequential increases of proliferating cell nuclear antigen expression in head and neck tumorigenesis: a potential biomarker. J. Natl. Cancer Inst. 85: 971-978, 1993.
24. Kurki, P. Ogata, K. and Tan, E.M. Monoclonal antibodies to proliferating cell nuclear antigen (PCNA)/cyclin as probes for proliferating cells by immunofluorescence microscopy and flow cytometry. J. Immunol. Methods, 109: 49-59, 1988.
25. Hall, P.A. Levison, D.A. Woods, A.L. Yu C.W. Kellock, D.B. Watkins, J.A. Barnes, D.M. Gillett, C.E. Camplejohn, R. Dover, R. Waseem, N.H. and Lane, D.P. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with the evidence of deregulated expression in some neoplasms. J. Pathol. 162: 285-294, 1990.
26. Bravo, R. Frank, R. Blundell, P.A. and MacDonald-Bravo, H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-ω. Nature (Lond.), 326: 515-517, 1987.
27. Prelich, G. Tan, C.K. Kostura, M. Mathews, M.B. So, A.C. Downey, K.M. and Stillman, B. Functional identity of proliferating cell nuclear antigen and a DNA polymerase-ω auxiliary protein. Nature (Lond.), 326: 517-520, 1987.
28. Shaw, G.L. Gazdar, A.F. Phelps, R. Linnoila, R.I. Ihde, D.C. Johnson, B.E. Oie, H.K. Pass, H.I. Steinberg, S.M. Ghosh, B.C. Walsh, T.E. Nesbitt, J.C. Cotelingam, J.D. Minna, J.D. and Mulshine, J.L. Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. Cancer Res. 53: 51585187, 1993.
29. Roos, G. Landberg, G. Huff, J.P. Houghten, Takasaki, Y. and Tan, E.M. Analysis of the epitopes of proliferating cell nuclear antigen recognized by monoclonal antibodies. Lab. Invest. 68: 204-210, 1993.
30. Linnoila, R.I. Mulshine, J.L. Steinberg, S.M. Funa, K. Matthews, M.J. Cotelingam, J.D. and Gazdar, A.F. Neuroendocrine differentiation in endocrine and neuroendocrine lung carcinomas. Am. J. Clin. Pathol. 90: 1-12, 1988.
31. Carey, E.A. Fabbroni, G. and Lamb, D. Expression of proliferating cell nuclear antigen in lung cancer: a systematic study and correlation with DNA ploidy. Histopathology, 20: 499-503, 1992.
32. Mehta, C.R. and Patel, N.R. A network algorithm for performing Fisher's exact test in r X c contingency tables. J. Am. Stat. Assoc. 78: 427-434, 1983.
33. Kaplan, E.L. and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53: 457-481, 1958.
34. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem. Rep. 50: 163-170, 1966.
35. Cox, D.R. Regression models and life-tables. J. Royal Stat. Soc. (B), 34: 187-202, 1972.
36. Matthews, D.E. and Farewell, V.T. Using and understanding medical statistics. Basel: Karger SA, 148-158, 1985.
37. Stevenson, H. Gazdar, A.F. Phelps, R. Linnoila, R.I. Ihde, D.C. Ghosh, B. Walsh, T. Woods, E.L. Oie, H. O'Connor, T. Makuch, R. Kramer, B.S. and Mulshine, J.L. Tumor cell lines established in vitro: an independent prognostic factor for survival in non-small cell lung cancer. Ann. Int. Med. 113: 764-770, 1990.
38. Iggo, R. Gatter, K. Bartek, J. Lane, D. and Harris, A.L. Increased expression of mutant forms of p. 3 oncogene in primary lung cancer. Lancet, 335: 675-679, 1990.
39. Noguchi, M. Maezawa, N. Nakanishi, Y. Matsuno, Y. Shimosato, Y. and Hirohashi, S. Application of the p. 3 gene mutation pattern for differential diagnosis of primary versus metastatic lung carcinomas. Diagn. Mol. Pathol. 2: 29-35, 1993.
40. Linnoila, R.I. Pathology of non-small cell lung cancer. Hematol. Oncol. Clin. N. Am. 4: 1027-1051, 1990.
41. Westra, W.H. Offerhaus, G.J.A. Goodman, S.N. Slebos, R.J. Polak, M. Baas, I.O. Rodenhuis, S. and Hruban, R.H. Overexpression of the p. 3 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am. J. Surg. Pathol. 17: 213-220, 1993.
42. Caamano, J. Ruggeri, B. Momiki, S. Sickler, A. Zhang, S.Y. and Klein-Szanto, A.J. Detection of p. 3 in primary lung tumors and non-small cell lung carcinoma cell lines. Am. J. Pathol. 139: 839-845, 1991.
43. Suzuki, H. Takahashi, T. Kuroishi, T. Suyama, M. Ariyoshi, Y. Takahashi, T. and Ueda, R. p. 3 mutation in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res. 52: 734-736, 1992.
44. Kishimoto, Y. Murakami, Y. Shiraishi, M. Hayashi, K. and Sekiya, T. Aberrations of the p. 3 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res. 52: 4799-4804, 1992.
45. Theunissen, P.H.M.H. Leers, M.P.G. and Bollen, E.C.M. Proliferating cell nuclear antigen (PCNA) expression in formalin-fixed tissue of non-small cell lung carcinoma. Histopathology, 20: 251-255, 1992.
46. Alama, A. Constantini, M. Repetto, L. Conte, P.F. Serrano, J. Nicolin, A. Barbieri, F. Ardizzoni, A. and Bruzzi, P. Thymidine labeling index as prognostic factor in resected non-small cell lung cancer. Eur. J. Cancer, 26: 622-625, 1990.
47. Hanna, R. Robinson, R. Kern, J. and Schwartz, D. Clinicopathologic correlation of proliferating cell nuclear antigen (PCNA) and neu expression in pulmonary adenocarcinoma. Lab. Invest. 68: 129A, 1993.
48. Brown, R.W. Fraire, A.E. Roggli, V. and Cagle, P.T. Assessment of proliferative fraction by PCNA in stage I non-small cell lung cancer. Lab. Invest. 68: 131 A, 1993.
49. van Dierendonck, J.H. Wijsman, J.H. Keijzer, R. van de Velde, C.J.H. and Cornelisse, C.J. Cell cycle related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki-67 staining. Am. J. Pathol. 138: 1165-1172, 1991.
50. Coltrera, M.D. and Gown, A.M. PCNA/cyclin expression and BrdU uptake define different subpopulations in different cell lines. J. Histochem. Cytochem. 39: 23-30, 1991.
51. Celis, J.E. and Celis, A. Cell cycle-dependent variation in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc. Natl. Acad. Sci. USA, 82: 3262-3266, 1985.
52. Frebourg, T. Kassel, J. Lam, K.T. Gryka, M.A. Barbier, N. Anderson, T.I. Borresen, A.L. and Friend, S.H. Germ-line mutations of the p. 3 tumor suppressor gene in patients with high risk for cancer inactivate the p. 3 protein. Proc. Natl. Acad. Sci. USA, 89: 6413-6417, 1992.